Impact Biomedical (IBO) Return on Capital Employed (2023 - 2026)
Impact Biomedical's (IBO) quarterly Return on Capital Employed came in at 34.71% in Q1 2026, up 24962.0% YoY from N/an in Q1 2025, and down 106.1% on a QoQ basis from 568.75% in Q3 2025.
Impact Biomedical (IBO) Return on Capital Employed (2023 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 4 years of Return on Capital Employed data on file, last reported at 34.71% in Q1 2026.
- Quarterly Return on Capital Employed rose 24962.0% year-over-year to 34.71% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34.71% (up 24962.0% YoY) and the FY2024 annual result came in at 126.8%, down 11438.0% from the prior year.
- Return on Capital Employed declined to 34.71% in Q1 2026, from 568.75% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 816.29% in Q2 2025 to a low of 284.32% in Q1 2025.
- A 4-year average of 88.68% and a median of 12.43% in 2023 frame the typical range for Return on Capital Employed.
- The widest YoY moves for Return on Capital Employed: up 82844 bps in 2025, down 27128 bps in 2025.
- Tracing IBO's Return on Capital Employed over 4 years: stood at 12.7% in 2023, then slumped by 855 bps to 121.29% in 2024, then surged by 569 bps to 568.75% in 2025, then slumped by 106 bps to 34.71% in 2026.
- The last three Return on Capital Employed figures came in at 34.71% (Q1 2026), 568.75% (Q3 2025), and 816.29% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | -34.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.24% |
| Mar 31, 2026 | -34.71% |
| Sep 30, 2025 | 568.75% |
| Jun 30, 2025 | 816.29% |
| Mar 31, 2025 | -284.32% |
| Dec 31, 2024 | -121.29% |
| Sep 30, 2024 | -8.27% |
| Jun 30, 2024 | -12.15% |
| Mar 31, 2024 | -13.04% |
| Dec 31, 2023 | -12.70% |
| Sep 30, 2023 | -11.79% |